Protéines de liaison au TGF-bêta latent : Questions médicales fréquentes
Nom anglais: Latent TGF-beta Binding Proteins
Descriptor UI:D053779
Tree Number:D12.776.860.300.688
Termes MeSH sélectionnés :
Cell Line
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Protéines de liaison au TGF-bêta latent : Questions médicales les plus fréquentes",
"headline": "Protéines de liaison au TGF-bêta latent : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Protéines de liaison au TGF-bêta latent : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-18",
"dateModified": "2025-04-14",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Protéines de liaison au TGF-bêta latent"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines de la matrice extracellulaire",
"url": "https://questionsmedicales.fr/mesh/D016326",
"about": {
"@type": "MedicalCondition",
"name": "Protéines de la matrice extracellulaire",
"code": {
"@type": "MedicalCode",
"code": "D016326",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.860.300"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Protéines de liaison au TGF-bêta latent",
"alternateName": "Latent TGF-beta Binding Proteins",
"code": {
"@type": "MedicalCode",
"code": "D053779",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Nalani Sachan",
"url": "https://questionsmedicales.fr/author/Nalani%20Sachan",
"affiliation": {
"@type": "Organization",
"name": "Department of Cell Biology, NYU Grossman School of Medicine, New York, New York, USA."
}
},
{
"@type": "Person",
"name": "Hui Liu",
"url": "https://questionsmedicales.fr/author/Hui%20Liu",
"affiliation": {
"@type": "Organization",
"name": "Department of Experimental Surgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, 710038, Shanxi, China."
}
},
{
"@type": "Person",
"name": "Daniel Rifkin",
"url": "https://questionsmedicales.fr/author/Daniel%20Rifkin",
"affiliation": {
"@type": "Organization",
"name": "Department of Cell Biology, NYU Grossman School of Medicine, New York, New York, USA."
}
},
{
"@type": "Person",
"name": "Karan Singh",
"url": "https://questionsmedicales.fr/author/Karan%20Singh",
"affiliation": {
"@type": "Organization",
"name": "Department of Cell Biology, NYU Grossman School of Medicine, New York, New York, USA."
}
},
{
"@type": "Person",
"name": "Hong-Lian Wang",
"url": "https://questionsmedicales.fr/author/Hong-Lian%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Research Center for Integrative Medicine, The Affiliated Traditional Medicine Hospital of Southwest Medical University, Luzhou 646000, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Efficacy analysis of HAIC combined with lenvatinib plus PD1 inhibitor vs. first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma.",
"datePublished": "2024-10-14",
"url": "https://questionsmedicales.fr/article/39397104",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-024-75102-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "A rapid and simple modified nitrate reductase assay for testing first and second-line antituberculosis drug susceptibilities in Mycobacterium tuberculosis isolates.",
"datePublished": "2024-09-26",
"url": "https://questionsmedicales.fr/article/39357107",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.diagmicrobio.2024.116547"
}
},
{
"@type": "ScholarlyArticle",
"name": "Efficacy and safety of the first-line systemic treatments in patients with advanced-stage urothelial carcinoma: a systematic review and network meta-analysis.",
"datePublished": "2024-09-16",
"url": "https://questionsmedicales.fr/article/39351347",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fonc.2024.1468784"
}
},
{
"@type": "ScholarlyArticle",
"name": "Analysis of correlation between medial joint line change and lower limb coronal alignment after Oxford unicompartmental knee arthroplasty.",
"datePublished": "2024-09-02",
"url": "https://questionsmedicales.fr/article/39226870",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clinsp.2024.100478"
}
},
{
"@type": "ScholarlyArticle",
"name": "Gaming Disorders: Navigating the Fine Line between Entertainment and Addiction-Gaming History, Health Risks, Social Consequences, and Pathways to Prevention.",
"datePublished": "2024-08-29",
"url": "https://questionsmedicales.fr/article/39274335",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/jcm13175122"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Scléroprotéines",
"item": "https://questionsmedicales.fr/mesh/D012596"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protéines de la matrice extracellulaire",
"item": "https://questionsmedicales.fr/mesh/D016326"
},
{
"@type": "ListItem",
"position": 6,
"name": "Protéines de liaison au TGF-bêta latent",
"item": "https://questionsmedicales.fr/mesh/D053779"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Protéines de liaison au TGF-bêta latent - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Protéines de liaison au TGF-bêta latent",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-16",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Protéines de liaison au TGF-bêta latent",
"description": "Comment diagnostiquer une anomalie des protéines de liaison au TGF-bêta ?\nQuels tests sont utilisés pour évaluer le TGF-bêta ?\nLes biopsies sont-elles nécessaires pour le diagnostic ?\nQuels symptômes peuvent indiquer un problème avec le TGF-bêta ?\nY a-t-il des marqueurs spécifiques pour ces protéines ?",
"url": "https://questionsmedicales.fr/mesh/D053779?mesh_terms=Cell+Line&page=998#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Protéines de liaison au TGF-bêta latent",
"description": "Quels symptômes sont associés à une dysfonction du TGF-bêta ?\nLa douleur est-elle un symptôme courant ?\nPeut-on observer des anomalies cutanées ?\nLes troubles respiratoires sont-ils liés au TGF-bêta ?\nY a-t-il des signes d'inflammation systémique ?",
"url": "https://questionsmedicales.fr/mesh/D053779?mesh_terms=Cell+Line&page=998#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Protéines de liaison au TGF-bêta latent",
"description": "Comment prévenir les troubles liés au TGF-bêta ?\nY a-t-il des mesures spécifiques à prendre ?\nLes vaccinations sont-elles importantes ?\nL'éducation des patients est-elle cruciale ?\nLe suivi médical régulier est-il recommandé ?",
"url": "https://questionsmedicales.fr/mesh/D053779?mesh_terms=Cell+Line&page=998#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Protéines de liaison au TGF-bêta latent",
"description": "Quels traitements sont disponibles pour les troubles liés au TGF-bêta ?\nLa thérapie génique est-elle une option ?\nLes corticostéroïdes sont-ils utilisés ?\nY a-t-il des traitements expérimentaux ?\nLes changements de mode de vie peuvent-ils aider ?",
"url": "https://questionsmedicales.fr/mesh/D053779?mesh_terms=Cell+Line&page=998#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Protéines de liaison au TGF-bêta latent",
"description": "Quelles complications peuvent survenir ?\nLes complications cardiovasculaires sont-elles possibles ?\nY a-t-il un risque accru de cancer ?\nLes troubles neurologiques peuvent-ils être liés ?\nComment gérer les complications ?",
"url": "https://questionsmedicales.fr/mesh/D053779?mesh_terms=Cell+Line&page=998#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Protéines de liaison au TGF-bêta latent",
"description": "Quels sont les principaux facteurs de risque ?\nLe vieillissement est-il un facteur de risque ?\nL'obésité influence-t-elle le risque ?\nLe stress a-t-il un impact ?\nLes infections peuvent-elles être un facteur ?",
"url": "https://questionsmedicales.fr/mesh/D053779?mesh_terms=Cell+Line&page=998#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie des protéines de liaison au TGF-bêta ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests sanguins et des analyses génétiques pour détecter des mutations."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer le TGF-bêta ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dosages immunologiques et des tests ELISA sont couramment utilisés pour mesurer le TGF-bêta."
}
},
{
"@type": "Question",
"name": "Les biopsies sont-elles nécessaires pour le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des biopsies peuvent être effectuées pour évaluer les tissus affectés et la présence de TGF-bêta."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec le TGF-bêta ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme l'inflammation chronique ou des troubles de cicatrisation peuvent indiquer un problème."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs spécifiques pour ces protéines ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des marqueurs comme le TGF-bêta actif peuvent être utilisés pour évaluer leur fonction."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés à une dysfonction du TGF-bêta ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des troubles immunitaires, des fibroses et des anomalies de cicatrisation."
}
},
{
"@type": "Question",
"name": "La douleur est-elle un symptôme courant ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs peuvent survenir en raison d'inflammation ou de fibrose tissulaire."
}
},
{
"@type": "Question",
"name": "Peut-on observer des anomalies cutanées ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies cutanées comme des cicatrices hypertrophiques peuvent se produire."
}
},
{
"@type": "Question",
"name": "Les troubles respiratoires sont-ils liés au TGF-bêta ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles respiratoires peuvent survenir en raison de fibrose pulmonaire associée."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes d'inflammation systémique ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des signes comme la fièvre et la fatigue peuvent indiquer une inflammation systémique."
}
},
{
"@type": "Question",
"name": "Comment prévenir les troubles liés au TGF-bêta ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par un mode de vie sain et la gestion des maladies inflammatoires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures spécifiques à prendre ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter le tabac et l'alcool peut réduire le risque de complications liées au TGF-bêta."
}
},
{
"@type": "Question",
"name": "Les vaccinations sont-elles importantes ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccinations peuvent aider à prévenir les infections qui exacerbent les troubles."
}
},
{
"@type": "Question",
"name": "L'éducation des patients est-elle cruciale ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, informer les patients sur les symptômes et les facteurs de risque est essentiel."
}
},
{
"@type": "Question",
"name": "Le suivi médical régulier est-il recommandé ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi médical régulier permet de détecter précocement les anomalies."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les troubles liés au TGF-bêta ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des médicaments anti-inflammatoires et des thérapies ciblées."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la thérapie génique est explorée pour corriger des anomalies génétiques liées au TGF-bêta."
}
},
{
"@type": "Question",
"name": "Les corticostéroïdes sont-ils utilisés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les corticostéroïdes peuvent être prescrits pour réduire l'inflammation associée."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements expérimentaux, comme les inhibiteurs de TGF-bêta, sont en cours d'évaluation."
}
},
{
"@type": "Question",
"name": "Les changements de mode de vie peuvent-ils aider ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des changements comme une alimentation saine et l'exercice peuvent améliorer les symptômes."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des fibroses, des troubles respiratoires et des maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Les complications cardiovasculaires sont-elles possibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications cardiovasculaires peuvent survenir en raison d'une inflammation chronique."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de cancer ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des études suggèrent un lien entre TGF-bêta et certains types de cancer."
}
},
{
"@type": "Question",
"name": "Les troubles neurologiques peuvent-ils être liés ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles neurologiques peuvent être associés à des déséquilibres du TGF-bêta."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des complications nécessite une approche multidisciplinaire et un suivi régulier."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des maladies auto-immunes et l'exposition à des toxines."
}
},
{
"@type": "Question",
"name": "Le vieillissement est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le vieillissement peut augmenter le risque de dysfonction des protéines de liaison au TGF-bêta."
}
},
{
"@type": "Question",
"name": "L'obésité influence-t-elle le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'obésité est associée à une inflammation chronique, augmentant le risque de troubles."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut exacerber les troubles liés au TGF-bêta."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles être un facteur ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines infections peuvent déclencher des réponses inflammatoires affectant le TGF-bêta."
}
}
]
}
]
}
This research was intended to compare the clinical efficacy of hepatic arterial infusion chemotherapy (HAIC) in conjunction with lenvatinib and PD1 inhibitors to first-line systemic chemotherapy for a...
In this study, we developed a modified NRA (MONRA) to determine the first and second-line drug susceptibilities of 5 reference ATCC strains and 42 clinical M. tuberculosis isolates. Unlike conventiona...
In recent years, some clinical studies of first-line treatment for advanced-stage urothelial carcinoma (aUC) have reached the main endpoint, showing inconsistent clinical efficacy. We hope to explore ...
The relevant literature from January 2000 to February 2024 was searched, and the R language (version 4.3.1) was used to perform a network meta-analysis based on the JAGS package and GEMTC package unde...
A total of 8 RCTs involving 5539 patients and 12 treatments were included. Pembrolizumab plus Enfortumab Vedotin (PEM+EV) was significantly better than other groups in OS, PFS and ORR. In terms of OS,...
PEM+EV can significantly prolong OS and PFS compared with other treatments, and has a higher ORR. The adverse events of grade 3 or higher of ATE was the lowest....
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024525372, identifier CRD42024525372....
Lower limb coronal alignment was thought to be a predictive factor for Unicompartmental Knee Arthroplasty (UKA) result. The tibial bony resection and implant position lead to joint line change postope...
From 2019 to 2021, 90 medial Oxford UKA were implanted by a single surgeon. Hip Knee Ankle Angle (HKAA), Lateral Distal Femoral Angle (LDFA), Medial Proximal Tibial Angle (MPTA), and intraoperative bo...
The mean tibial resection thickness was 4.3 mm. The mean tibial joint line was elevated by 2.3 mm, while the mean femoral joint line proximalized by 0.8 mm. HKAA changed from 8.4° varus preoperatively...
The change of joint line had no correlation with postoperative HKAA in Oxford UKA. Preoperative HKAA strongly correlated with postoperative HKAA; while preoperative smaller LDFA and larger MPTA had a ...
The number of people immersed in excessive gaming has increased in this age of rapid digitalization. The World Health Organization and American Psychiatric Association Organization recognize a gaming ...
Although treatment outcomes for metastatic colorectal cancer (mCRC) have dramatically improved over the past few decades, drug costs have also significantly increased. This study aimed to investigate ...
We collected data on patients with mCRC who received first-line treatment at 37 institutions of the Japan Clinical Oncology Group Colorectal Cancer Study Group from July 2021 to June 2022, and calcula...
The study included 1880 participants, 24% of whom were ≥ 75 years. Molecular targeted containing regimens were received by 78% of the patients. The most frequently used regimen was the doublet regimen...
About 16% of mCRC patients received first-line treatment with regimens costing >500 000JPY/month, and molecular targeted drugs being the main drivers of cost....
This study aimed to investigate the effect of changing the indoor unit air flow rate on the performance of an automobile heat pump with a suction line heat exchanger. Using a four-way valve, the autom...
To present the real-world status and explore the predictors of the efficacy and prognosis of first-line treatment for unresectable hepatocellular carcinoma (uHCC)....
Real-world data of uHCC patients who underwent first-line treatment at 4 hospitals in Northern Anhui, China, from July 2019 to December 2022 were retrospectively collected. The clinicopathological fea...
A total of 153 patients were enrolled and most of them treated with targeted therapy combined with immunotherapy (TI). Compared to patients treated with TI, patients who were administrated with TI plu...
TI was the most commonly first-line systemic therapy for uHCC patients, with better efficacy and outcomes when combined with locoregional therapy in a certain population. Baseline serum SOD and VEGF-A...
Until recently, the standard first-line treatment for advanced urothelial carcinoma (UC) was platinum-based combination chemotherapy followed by avelumab maintenance therapy for patients without progr...
Patients with advanced UC that progressed or recurred after first-line platinum-based chemotherapy were randomly assigned 1:1 to receive either pembrolizumab 200 mg every 3 wk (Q3W) for ≤2 yr or inves...
An objective response to pembrolizumab was observed in all groups in terms of a prior response to first-line platinum-based chemotherapy. Median OS, ORR, and median DOR were numerically greater with p...
When compared with chemotherapy, prolonged OS and durable responses to second-line pembrolizumab were observed independently of the response to or type of prior platinum-based chemotherapy. These find...
The access of new energy improves the flexibility of distribution network operation, but also leads to more complex mechanism of line loss. Therefore, starting from the nonlinear, fluctuating and mult...